Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Troglitazone21 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A02012 | 34531129 | Dig Liver Dis | Troglitazone inhibits hepatic oval cell proliferation by inducing cell cycle arrest through Hippo/YAP pathway regulation. | 2021 | Details |
| A07293 | 32553762 | Gastroenterology | Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease. | 2020 | Details |
| A14410 | 29420067 | Am J Physiol Gastrointest Liver Physiol | Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury. | 2018 | Details |
| A22471 | 24534255 | Toxicol Appl Pharmacol | PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. | 2014 | Details |
| A22551 | 24469900 | Arch Toxicol | A simple transcriptomic signature able to predict drug-induced hepatic steatosis. | 2014 | Details |
| A24561 | 22749137 | J Nutr Biochem | Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. | 2012 | Details |
| A24915 | 22364184 | J Agric Food Chem | Synergistic effect of cyanidin and PPAR agonist against nonalcoholic steatohepatitis-mediated oxidative stress-induced cytotoxicity through MAPK and Nrf2 transduction pathways. | 2012 | Details |
| A26709 | 19921118 | Adv Ther | Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. | 2009 | Details |
| A27587 | 17983937 | Endocrinol Metab Clin North Am | Use of insulin sensitizers in NASH. | 2007 | Details |
| A28077 | 16503761 | Expert Opin Investig Drugs | Recent findings concerning thiazolidinediones in the treatment of diabetes. | 2006 | Details |
| A28479 | 12739988 | Expert Opin Pharmacother | Current best treatment for non-alcoholic fatty liver disease. | 2003 | Details |
| A28565 | 10902968 | Liver | The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. | 2000 | Details |
| A35964 | 19318980 | J Clin Gastroenterol | Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation? | 2009 | Details |
| A37238 | 16198619 | Hepatol Res | Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection. | 2005 | Details |
| A38179 | 11965828 | Int J Clin Pract Suppl | Thiazolidinedione hepatotoxicity: a class effect? | 2000 | Details |
| A38390 | 11374713 | Am J Gastroenterol | Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. | 2001 | Details |
| A38442 | 11232700 | Am J Gastroenterol | A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. | 2001 | Details |
| A44344 | 28903485 | Toxicol Sci | Editor's Highlight: Mechanistic Toxicity Tests Based on an Adverse Outcome Pathway Network for Hepatic Steatosis. | 2017 | Details |
| A46743 | 15989845 | Med Clin (Barc) | [Medical management of primary nonalcoholic fatty liver disease]. | 2005 | Details |
| A48429 | 11232664 | Am J Gastroenterol | Insulin resistance and nonalcoholic steatohepatitis: fat or fiction? | 2001 | Details |
| A49192 | 14585066 | Expert Opin Drug Saf | Hepatotoxicity of thiazolidinediones. | 2003 | Details |